Inogen (6IO) AI Stock Analysis

Inogen

(BX Swiss:6IO)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

International growthSustained double-digit international growth indicates expanding adoption and geographic reach for Inogen’s products. A diversified international contribution can reduce reliance on U.S. channels, support scale, and provide a durable avenue for revenue growth over the next several quarters.

Negative Factors

Persistent losses and cash burnRevenue and gross margin improvements have not yet translated into sustainable GAAP earnings or consistently positive cash generation. Continued losses and negative free cash flow could consume balance-sheet resources, limit reinvestment capacity, and delay a self-funded recovery.

Inogen Business Overview & Revenue Model

Company Description

Inogen, Inc. operates as a medical technology enterprise dedicated to designing, fabricating, and distributing oxygen concentration equipment. These cutting-edge devices are engineered to provide continuous oxygen support for patients managing persis...

Inogen Earnings Call Summary

Earnings Call Date:Aug 05, 2026(Q2-2026)|Next Earnings Date:Nov 04, 2026

Earnings Call SentimentNeutral

The call highlighted clear commercial and product progress — notably strong international revenue growth (+15% YoY), continued POC unit expansion (>12% YoY), early traction for new products (Voxi shipments >5,000; Aurora account count doubled), margin improvement (adjusted gross margin +65 bps) and a raised adjusted EBITDA outlook. Offsetting these positives are ongoing headwinds in the U.S. DTC channel (U.S. sales -2% YoY), a 12% decline in rental revenue, a downward revision to full-year revenue guidance (midpoint reduction of ~ $11.5M), and continued dependency on distributor purchase timing and reimbursement/regulatory milestones. Overall the company shows momentum in strategic growth areas and improved unit economics, but macro and channel mix pressures keep near-term top-line growth constrained.

Positive Updates

Total Revenue Growth

Total revenue of $95.1 million in Q2 2026, up 3% year-over-year, driven by international growth, POC demand, and contributions from new products Voxi and Aurora.

Negative Updates

U.S. Revenue Decline

U.S. sales were $42.3 million, down 2% year-over-year as B2B gains did not fully offset pressure in the direct-to-consumer (DTC) channel.

Company Guidance

Inogen updated full‑year 2026 revenue guidance to $355–$361 million (≈3% growth at the midpoint), down from a prior $366–$373 million range, and raised full‑year adjusted EBITDA guidance to about $4.0 million (≈48% growth versus $2.7M in 2025); Q3 revenue is expected to be roughly in line with Q3 2025 ($92.4M). In Q2 the company reported $95.1M revenue (+3% YoY), adjusted EBITDA $2.4M (+15% YoY), adjusted gross margin 45.6% (up 65 bps), total gross margin 45.5%, GAAP net loss $(3.9)M (adjusted net loss < $0.1M, ~95% improvement), operating cash flow $2.9M, free cash flow $1.0M, cash of ~$106.8–$107M, no debt, and repurchased ~1.1M shares for $7.5M YTD. Management’s guidance assumes continued strong POC demand (U.S. unit volume +12%), international strength ($41.3M, +15% and 10th consecutive quarter of double‑digit growth) and accelerating contributions from new products (Voxi/Aurora contributing >100 bps), offset partially by ongoing DTC channel mix pressure, U.S. rental declines ($11.6M, -12%), and timing of select international distributor purchases.

Inogen Risk Analysis

Inogen disclosed 62 risk factors in its most recent earnings report. Inogen reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

1 New Risk

1.We are subject to risks associated with public health threats and epidemics, including the COVID-19 PHE.Q3, 2020

Inogen Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

CH:6IO against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ELMD	71Outperform	$224.08M	19.74	23.38%	―	15.28%	53.24%
LIVN	69Neutral	$4.35B	22.89	15.41%	―	12.39%	―
VMD	64Neutral	$368.31M	25.64	10.30%	―	25.21%	6.14%
OM	53Neutral	$75.67M	-0.98	-62.25%	―	-1.26%	79.82%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
XTNT	45Neutral	$39.31M	-3.40	-23.45%	―	-14.27%	-132.84%

* Healthcare Sector Average

Performance Comparison

CH:6IO and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
ELMD	Electromed	27.04	2.11	8.46%
LIVN	LivaNova PLC	78.97	25.03	46.40%
XTNT	Xtant Medical Holdings Inc	0.28	-0.46	-62.26%
VMD	Viemed Healthcare US	9.67	3.13	47.86%
OM	Outset Medical, Inc.	4.03	-8.74	-68.44%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Inogen AI Stock Analysis